Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 2Withdrawn 1Unknown 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 220Urinary Bladder Neoplasms 54Carcinoma, Renal Cell 53Neoplasms 27Non-Muscle Invasive Bladder Neoplasms 26Kidney Neoplasms 25Breast Neoplasms 17Carcinoma, Transitional Cell 15Adenocarcinoma 15Melanoma 11Disease 11Neoplasm Metastasis 10Colorectal Neoplasms 10Uterine Cervical Neoplasms 9Endometrial Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 7Ovarian Neoplasms 7Lung Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Triple Negative Breast Neoplasms 6Testicular Neoplasms 6Recurrence 6Urologic Neoplasms 5Urinary Incontinence 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5

Interventions

ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms, Glandular and Epithelial × Genitourinary × Clear all
NCT07574541 2026-06-04

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡